Soumit Roy
Stock Analyst at Jones Trading
(1.65)
# 3,271
Out of 4,902 analysts
42
Total ratings
21.88%
Success rate
-3.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARA Protara Therapeutics | Initiates: Buy | $21 | $3.11 | +575.24% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $22.13 | +80.75% | 1 | May 20, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $22.69 | +19.02% | 2 | May 16, 2025 | |
| ACRV Acrivon Therapeutics | Downgrades: Hold | n/a | $1.35 | - | 2 | May 16, 2025 | |
| ONCY Oncolytics Biotech | Downgrades: Hold | n/a | $1.26 | - | 2 | May 16, 2025 | |
| MURA Mural Oncology | Downgrades: Hold | n/a | $2.49 | - | 2 | Mar 25, 2025 | |
| CRVO CervoMed | Upgrades: Buy | $15 | $7.41 | +102.43% | 3 | Mar 13, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $10 | $2.30 | +334.78% | 1 | Mar 12, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $34 | $20.80 | +63.46% | 2 | Mar 10, 2025 | |
| INAB IN8bio | Upgrades: Buy | $36 | $2.16 | +1,566.67% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $2.32 | +1,279.31% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.87 | - | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $9.31 | -3.33% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $11.04 | +53.99% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.77 | +369.31% | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $4 | $0.75 | +430.93% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.23 | - | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.63 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $7.53 | +245.29% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $26.41 | +165.05% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $46.79 | -78.63% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.77 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $10.72 | +646.27% | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.86 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $4.51 | +6,995.34% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $4.66 | +17,281.97% | 1 | Feb 24, 2021 |
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $3.11
Upside: +575.24%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $22.13
Upside: +80.75%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $22.69
Upside: +19.02%
Acrivon Therapeutics
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.35
Upside: -
Oncolytics Biotech
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.26
Upside: -
Mural Oncology
Mar 25, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.49
Upside: -
CervoMed
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $7.41
Upside: +102.43%
Nuvation Bio
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $2.30
Upside: +334.78%
Beam Therapeutics
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $20.80
Upside: +63.46%
IN8bio
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $2.16
Upside: +1,566.67%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $2.32
Upside: +1,279.31%
Nov 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.87
Upside: -
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $9.31
Upside: -3.33%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $11.04
Upside: +53.99%
Sep 17, 2024
Initiates: Buy
Price Target: $13
Current: $2.77
Upside: +369.31%
Sep 11, 2024
Maintains: Buy
Price Target: $6 → $4
Current: $0.75
Upside: +430.93%
Jul 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.23
Upside: -
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.63
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $7.53
Upside: +245.29%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $26.41
Upside: +165.05%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $46.79
Upside: -78.63%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $3.77
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: $10.72
Upside: +646.27%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.86
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $4.51
Upside: +6,995.34%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $4.66
Upside: +17,281.97%